Abstract Global coronavirus disease 2019 (COVID‐19) pandemics highlight the need of
developing vaccines with universal and durable protection against emerging SARS‐CoV‐2 …

Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic that has wreaked havoc …

Emerging SARS-CoV-2 variants and the gradually decreasing neutralizing antibodies over
time post vaccination have led to an increase in incidents of breakthrough infection across …

The glycosylated receptor-binding domain (glycoRBD) of SARS-CoV-2 can induce
protective neutralizing antibodies to function as a vaccine. However, it is unclear whether …

Novel adjuvants are highly desired to improve immune responses of SARS‐CoV‐2
vaccines. This work reports the potential of the stimulator of interferon genes (STING) …

Safety profiles and humoral responses to inactivated severe acute respiratory syndrome
coronavirus 2 (SARS‐CoV‐2) vaccines have been previously assessed, but cellular immune …

Since September 2020, the world has had more than 28 million cases of coronavirus
disease 2019 (COVID-19). Many countries are facing a second wave of the COVID-19 …

To fight against the worldwide COVID-19 pandemic, the development of an effective and
safe vaccine against SARS-CoV-2 is required. As potential pandemic vaccines, DNA/RNA …

SARS-CoV-2 has caused a global pandemic, infecting millions of people. An effective
preventive vaccine against this virus is urgently needed. Here, we designed and developed …

The hepatitis B virus core antigen (HBcAg) tolerates insertion of foreign epitopes and
maintains its ability to self‐assemble into virus‐like particles (VLPs). We constructed a∆ …